Pathstone Family Office’s Core Laboratories CLB Stock Holding History

Pathstone Family Office’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-191	Closed	-$13K	–	682
2019 Q1	$13K	Hold	191	–	–	﹤0.01%	477
2018 Q4	$11K	Buy	+191	New	+$16.5K	﹤0.01%	316

Other funds holding CLB

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Pathstone Family Office's CLB Position: Q2 2019 in Review

Pathstone Family Office sold out of Core Laboratories (CLB) in Q2 2019, closing a stake of 191 shares — an estimated $13K sold.

Pathstone Family Office first reported a position in CLB in Q4 2018 and held it in 2 quarters. The position peaked at $13K in Q1 2019. 304 funds tracked by Wall St. Rank hold CLB as of Q2 2019.

Pathstone Family Office reported no remaining Core Laboratories position as of Q2 2019 after selling out during the quarter.
Pathstone Family Office sold 191 Core Laboratories shares in Q2 2019, an estimated $13K.
Pathstone Family Office first reported a position in Core Laboratories in Q4 2018 and held it in 2 quarters.
Pathstone Family Office's Core Laboratories position peaked at $13K in Q1 2019.
304 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2019.

Based on Pathstone Family Office's 13F filing for Q2 2019, filed 14 Aug 2019.